Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common of which is Alzheimer's disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 individuals with PSP (cases) and 3,247 controls (stage 1) followed by a second stage in which we genotyped 1,051 cases and 3,560 controls for the stage 1 SNPs that yielded P ≤ 10(-3). We found significant previously unidentified signals (P < 5 × 10(-8)) associated with PSP risk at STX6, EIF2AK3 and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response and for a myelin structural component.     

PA6 Obtained by Polymerization with Trifunctional Regulators and Its DSC Results

Hydrolytic polymerization of 8 - caprolactam is carried out by the use of trimesinic acid as molecular weight controlling agent, and polyamide 6 with three branched chains is obtained. The initial concentrations of regulators almost have no effect on the conversion of caprolactam , while relative viscosity of the polymer is affected by the concentrations. DSC investigation shows that DSC curve changes from single peak for regular polyamide 6 to one peak with one shoulder or one small peak for polyamide 6 with three branched chains and the melting point decreases with the increase of the amount of trimesinic acid. In addition, the concentration of trimesinic acid being the same, DSC curves change from almost sharp single peak to double peak with increasing reaction time.